Customized Solutions for Post-Traumatic Osteoarthritis (PTOA) Model Development
Download
Post‑traumatic osteoarthritis (PTOA) is a degenerative joint disease that arises following a known mechanical insult or traumatic injury to the articular joint. Traumatic destabilizing injuries to the knee, particularly anterior cruciate ligament tears, meniscal tears, and intra‑articular fractures, significantly increase the risk of developing osteoarthritis in middle age.
As a full‑service preclinical research service provider, Protheragen specializes in the development and characterization of translational PTOA animal models that recapitulate the pathological changes observed in human disease. Leveraging extensive expertise in surgical and non‑surgical induction techniques, we offer customizable PTOA model development alongside a comprehensive suite of integrated preclinical research services, encompassing diagnostic development, therapeutic development, disease model development, and pharmacokinetic and toxicology evaluation, to accelerate the journey from target discovery to IND‑enabling studies.
Overview of Post-Traumatic Osteoarthritis (PTOA) Models
Post-traumatic osteoarthritis (PTOA) accounts for a significant proportion of all clinical osteoarthritis cases, frequently arising from intra-articular fractures, ligamentous ruptures, or meniscal tears that trigger localized mechanical stress and a persistent acute-to-chronic inflammatory response. Preclinical PTOA models are carefully designed to recapitulate this pathological cascade, initiating and driving cartilage matrix erosion, subchondral bone remodeling, synovial inflammation, and osteophyte formation under controlled laboratory conditions. Utilizing precise surgical interventions or non-invasive mechanical overload protocols, these models provide an invaluable platform for dissecting early peri-injury molecular mechanisms and monitoring time-dependent structural deterioration.
Applications of PTOA Animal Models
Deciphering the acute and chronic phases of post-traumatic joint degeneration relies on robust, reproducible animal models that capture the full continuum of tissue damage. These specialized translational systems serve several pivotal functions in drug discovery and therapeutic validation.
Unraveling Pathomechanisms
Elucidating acute post-injury inflammatory cascades, cartilage extracellular matrix turnover, and progressive subchondral bone sclerosis.
Target Identification & Validation
Evaluating novel molecular targets involved in chondrocyte apoptosis, mechanotransduction, and synovitis progression.
Therapeutic Efficacy Screening
Assessing disease-modifying osteoarthritis drugs, biologics, and small-molecule candidates across critical therapeutic windows.
Biomarker Discovery
Identifying and validating fluid-based molecular indicators and non-invasive imaging markers associated with early joint deterioration.
Workflow for PTOA Animal Model Development
- Project Design & Protocol Consultation: Defining specific study objectives, selecting optimal species or strains, and establishing precise mechanical or surgical dosing strategies tailored to target biology.
- Model Induction & Surgical Execution: Executing controlled surgical interventions or non-invasive mechanical loading under strict sterile conditions to guarantee consistent joint injury across groups.
- Longitudinal In Vivo Monitoring: Performing non-invasive micro-CT imaging, pain behavior assessments, and serum/synovial fluid sampling at predetermined temporal post-injury milestones.
- Comprehensive End-Point Analysis: Executing systematic histopathological scoring, micro-CT structural quantification, gene expression profiling, and tissue-level biochemical assaying for final evaluation.
Available PTOA Animal Models
Model |
Strain |
Application |
|---|---|---|
Destabilization of the Medial Meniscus (DMM) |
Mouse, Rat |
Studies on early OA mechanisms, genetic screening, and molecular pathways. |
Anterior Cruciate Ligament Transection (ACLT) |
Rat |
Testing intra articular injections, sustained release formulations, and structure modifying effects. |
Medial Meniscal Transection (MMT) |
Rat |
Functional recovery assessment, pain evaluation, and local repair testing. |
Partial Medial Meniscectomy (pMMx) |
Rat, Rabbit |
Drug efficacy evaluation, pain behavior analysis, and gait studies. |
ACLT + DMM (Combination) |
Rat, Rabbit |
Evaluation of combined injury, short term efficacy, and pain endpoints. |
… |
… |
… |
Integrated Preclinical Research Services for PTOA
Beyond model development, Protheragen provides a fully integrated suite of preclinical services designed to support every phase of PTOA therapeutic development within a single, seamless workflow.
Develops and validates molecular, imaging, and biochemical biomarkers for early PTOA detection, disease monitoring, and individual stratification, leveraging advanced platforms including multiplex ELISA, qRT‑PCR, immunohistochemistry, and high‑resolution micro‑CT imaging.
Evaluates the efficacy of small molecules, biologics, gene therapies, and cell‑based interventions in PTOA models, with comprehensive outcome measures including cartilage integrity, synovial inflammation, subchondral bone remodeling, and pain‑related behaviors.
Designs and characterizes custom PTOA models tailored to specific injury types, disease severities, and species requirements, with full histopathological, biochemical, and molecular characterization to ensure translational relevance.
Conducts PK/PD profiling, bioavailability studies, joint residence time analysis, and repeat‑dose toxicology assessments in animal models to support dose selection, safety margins, and IND‑enabling data packages.
Case Study 01-DMM Rat Model
Surgically induced destabilization of the medial meniscus (DMM) was performed on the right knee joint of male Sprague-Dawley (SD) rats to establish a progressive model of post-traumatic osteoarthritis. Following surgical induction, longitudinal functional readouts were monitored to track the onset and progression of joint degeneration. Functional pain assessments revealed a distinct reduction in right hindlimb weight-bearing percentage, capturing a dynamic shift in postural weight distribution indicative of movement-evoked chronic osteoarthritic pain. In parallel, quantitative evaluations encompassing joint nociception thresholds, system-level growth metrics, and terminal histopathology confirmed the successful recapitulation of progressive joint pathology.
Fig.1 (A) Body weight progression recorded across time points, highlighting a reduced growth velocity in the DMM surgical cohort relative to the age-matched Sham group; (B) Longitudinal measurements of Paw Withdrawal Threshold (PWT), illustrating persistent mechanical allodynia and hyperalgesia secondary to surgical joint destabilization. Data are presented as mean ± SEM (n=6).
Case Study 02-ACLT+DMM Rat Model
Surgically combining anterior cruciate ligament transection with destabilization of the medial meniscus (ACLT+DMM) in the right knee joint of Lewis rats established a robust model of severe post-traumatic osteoarthritis. Post-operative evaluations captured acute joint inflammation and altered biomechanical loading through serial measurements of knee joint dimensions and hindlimb weight distribution. Quantitative histopathological scoring via the Mankin system further confirmed significant articular cartilage breakdown, extensive proteoglycan exhaustion, and progressive subchondral bone architectural remodeling following combined surgical trauma.
Fig.2 (A) Longitudinal knee swelling difference assessments reflecting immediate post-operative inflammatory effusion and persistent structural swelling in the operated limb; (B) Dynamic shifts in right hindlimb weight-bearing percentage demonstrating sustained postural offloading and movement-evoked discomfort post-induction. Data are presented as mean ± SEM (n=6).
Case Study 03-ACLT+DMM Rabbit Model
Surgically performing a combined anterior cruciate ligament transection and destabilization of the medial meniscus (ACLT+DMM) on the right knee joint of New Zealand White Rabbits successfully modeled advanced post-traumatic osteoarthritis. Tracking disease progression through serial physical measurements revealed a clear shift from acute post-surgical swelling to chronic structural alterations in the joint capsule, alongside systemic physiological responses. High-resolution micro-CT imaging and post-mortem histopathology further confirmed marked subchondral bone remodeling, cartilage degeneration, and prominent peri-articular osteophyte development in the injured knee.
Fig.3 (A) Longitudinal right knee joint diameter tracking, recording the progression from initial inflammatory edema to chronic joint capsule thickening and osteophytic enlargement; (B) Longitudinal body weight dynamics, demonstrating an attenuated weight gain trajectory in the ACLT+DMM cohort compared to age-matched Sham controls over the observation window. Data are presented as mean ± SEM (n=6).
Why Choose Us?
- Deep Expertise in Pathophysiology: Possesses extensive experience across the full spectrum of PTOA induction methods, from surgical ACLT and DMM to non‑invasive mechanical rupture, ensuring models that reflect human disease mechanisms and progression.
- Comprehensive Multi‑Species Platform: Offers models across mouse, rat, rabbit, dog, and pig, enabling seamless translation from early‑stage target validation through to large‑animal efficacy and safety studies.
- Integrated End‑to‑End Service Model: Provides a unified workflow encompassing model development, therapeutic efficacy testing, biomarker discovery, pharmacokinetics, and toxicology, accelerating program timelines.
- Rigorous Quality: Employs standardized surgical protocols, validated outcome measures, and strict quality control procedures to deliver consistent, reliable data that supports regulatory decision‑making.
Contact Us
Protheragen is uniquely positioned to support the development of next‑generation therapeutics for PTOA through specialized disease model development and comprehensive integrated preclinical services. From custom model design through to IND‑enabling toxicology studies, our team delivers the scientific rigor, translational insight, and operational excellence required to advance your program with confidence. To discuss how we can support your PTOA research objectives, please contact us today.
Resource Download Request
Please complete the form to download the requested resources.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.